How to successfully apply for, administer, and manage the Zithromax® donation for trachoma elimination
More and more countries are completing their epidemiological mapping of trachoma in suspected
endemic districts and are preparing to distribute Zithromax® in those districts where the prevalence of
“trachomatous inflammation – follicular” (TF) is above 5% among children aged 1-9 years. Mass... drug
administration (MDA) is normally at the district level and targets the whole population with Zithromax®
tablets to those 5 years old and above; Zithromax® suspension for children between 6 months and 5
years of age; and tetracycline eye ointment 1% for infants up to 6 months old.
more
ICTC’s 2022-2030 strategic plan spans the critical period running to the end of 2030, the year by which we are striving to achieve the elimination of trachoma as a public health problem. This strategic plan is in alignment with the NTD road map, Ending the neglect to attain the Sustainable Develop...ment Goals: a road map for neglected tropical diseases 2021−2030.
more
The WHO Vision and eye screening implementation handbook (VESIH) offers a step-by-step guidance for conducting vision and eye screenings in community and primary care settings. The evidence-based interventions are drawn from the WHO Package of eye care interventions and developed with a focus on del...ivering screenings easily, safely, and effectively in low- and low–intermediate-resource settings. The early identification through screenings ensures timely treatments and management to avoid vision impairment in high-risk populations, including newborns, pre-school children, school children, and older adults.
more
The WHO Cholera Vaccine Position Paper (August 2017) highlights the importance of oral cholera vaccines (OCVs) as a key tool in outbreak response and prevention, alongside water, sanitation, and hygiene (WASH) measures. It recommends OCVs for high-risk populations, endemic areas, and humanitarian cr...ises, emphasizing their effectiveness in reducing cases and mortality. The paper discusses two types of OCVs (Dukoral®, Shanchol™, Euvichol®) and supports the WHO-managed vaccine stockpile for rapid deployment in cholera-prone regions.
more
This annual report gives an overview of WHO lesotho Country office's undertakings and achievements in the context of an extraordinary health emergency. As we walk another mile this year, may we embrace all lessonst leanred in the previous year, learn from what did not work so well and take on new op...portunities in championing health in the country.
more
This profile is part of a series of Climate Risk Country Profiles developed by the World Bank Group (WBG). The country profile
synthesizes most relevant data and information on climate change, disaster risk reduction, and adaptation actions and policies
at the country level. The country profile se...ries are designed as a quick reference source for development practitioners to better
integrate climate resilience in development planning and policy making.
more
In March 2020, the World Health Organization (WHO) declared that the outbreak of COVID-19, the disease caused by a new coronavirus, constituted a pandemic, given the speed and scale of its transmission. The Region of the Americas is characterized by its rich multi-ethnic and multicultural heritage. ...Nonetheless, indigenous peoples, Afro-descendants, and other ethnic groups are often subject to discrimination and exclusion, resulting in health inequities. COVID-19 may have a greater impact on certain populations, such as indigenous peoples and Afro-descendants.
more
Policy note: Cambodia Health Systems in Transition.
The health system includes a mix of public and private providers. The use of private providers is much greater among the wealthy, while the use of informal-sector health providers is greater among the poor. Due to these circumstances there is ...considerable scope to establish appropriate public-private cooperation and to reinforce the regulatory mandate of the Ministry of Health (MOH).
more
Document No. : FDA/SMC/SMD/GL-SMP/2015/05 |
These guidelines are for information, guidance and strict compliance by Marketing Authorization Holders and Local Representatives of regulated products to help in the continuous safety monitoring of products granted marketing authorization in Ghana.